Monoclonal antibodies (MAbs) remain the dominant biopharmaceutical product class, but as biotechnologies have advanced in recent decades, developers have found ways to exploit their “magic-bullet” capabilities while putting aside their limitations. This has led to a new generation of antibody-related therapeutics created by cutting and pasting molecular domains.
Researchers are mixing and matching functional moieties of antibodies and other molecules to create custom-designed proteins with powerful efficacy and tunable targeting. Many avenues have been pursued to improve the monoclonal antibody paradigm, leading to the development of new monoclonals and antibody-derived therapeutic proteins. Derivatives include modified intact antibodies with modulated effector functions, bispecific and multi-specific antibodies, and antibody fragments.
We will be establishing an increase in production capabilities in the near future.